Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE A IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Maintenance and restoration of fluid and electrolyte balance; provides isotonic crystalloid solution with sodium, potassium, magnesium, chloride, and acetate/bicarbonate precursors to buffer acidity.
Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.
Replacement of acute extracellular fluid volume deficits,Correction of metabolic acidosis,Maintenance fluid therapy in patients requiring electrolyte replacement
Source of electrolytes, calories, and water for hydration in patients with or without carbohydrate deficiency,Maintenance and replacement of fluid and electrolyte losses in pediatric patients,Treatment of hypophosphatemia,Off-label: Total parenteral nutrition component
Intravenous infusion; adult dose is based on electrolyte and fluid requirements, typically 500-1000 m L/hour initially, then adjusted; maximum rate 30 m L/kg/hour.
Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.
Not applicable as a single half-life; electrolytes have distribution and elimination phases governed by body stores and renal function. For water, elimination half-life is ~2-4 hours in euvolemic individuals with normal GFR. Clinically, infused volume distributes within ~30 minutes and is renally cleared over several hours.
Dextrose has a half-life of approximately 1.5–3 hours in patients with normal glucose metabolism; in renal failure, electrolyte half-lives may be prolonged. The half-life of sodium is about 2–4 hours, and potassium 2–6 hours, depending on renal function.
Acetate and gluconate are metabolized to bicarbonate primarily in the liver and kidneys; electrolytes are excreted unchanged via kidneys.
Dextrose is metabolized via glycolysis to pyruvate then enters the TCA cycle. Acetate is metabolized via TCA cycle to bicarbonate. Phosphate is excreted renally or incorporated into ATP and other compounds.
Electrolytes and water are primarily excreted renally: sodium (90-95% filtered, reabsorbed), chloride (follows sodium), potassium (80-90% renal, 10% fecal), magnesium (30-50% reabsorbed, remainder excreted), acetate (metabolized to bicarbonate, ultimately renal). Fluid volume is regulated by renal mechanisms (ADH, aldosterone). Essentially 100% of administered volume and electrolytes are eliminated via kidneys under normal physiology.
Electrolytes are primarily excreted via renal pathways; dextrose is metabolized to CO2 and water, with negligible renal excretion. Specifically, sodium, potassium, magnesium, chloride, acetate, and gluconate are eliminated by the kidneys, with over 90% of infused electrolytes excreted renally.
None significant; electrolytes are free in plasma (sodium, chloride, potassium, magnesium are not protein-bound). Acetate is rapidly metabolized.
Sodium, potassium, chloride, magnesium, and acetate have negligible protein binding (<5%); calcium is ~45% bound to albumin; gluconate binding is minimal.
Electrolytes: 0.2 L/kg for sodium and chloride (extracellular fluid); water: total body water ~0.6 L/kg. Clinical meaning: Vd of electrolytes approximates ECF volume; water distributes throughout total body water.
Electrolytes distribute into total body water, approximately 0.6 L/kg for adults; dextrose distributes into extracellular fluid (~0.2 L/kg) but is rapidly taken up by cells.
Not applicable for IV route; bioavailability is 100% by definition.
Intravenous: 100% bioavailability.
No specific GFR-based dose adjustment; contraindicated in severe renal impairment with oliguria or anuria.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of hyperkalemia and fluid overload; for GFR 30-50 m L/min, use with caution and monitor potassium and fluid status.
No specific Child-Pugh based adjustment; use with caution in severe hepatic impairment due to risk of electrolyte imbalances.
No specific dose adjustment for Child-Pugh class; use with caution in severe hepatic impairment due to risk of fluid overload and electrolyte imbalances.
Intravenous infusion; dose based on weight: 5-20 m L/kg/hour initially, adjusted according to clinical response and laboratory values; maximum 50 m L/kg/day.
Intravenous infusion at a rate of 100-150 m L/kg/day for maintenance, adjusted based on weight, clinical condition, and electrolyte requirements.
Use with caution due to increased risk of fluid overload and electrolyte disturbances; monitor renal function and adjust rate accordingly.
Use with caution due to decreased renal function; start at lower infusion rates (e.g., 0.5-1 L per 24 hours) and monitor fluid and electrolyte status closely.
None
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to any component. Do not administer simultaneously with blood products through the same set due to risk of hemolysis.
Use with caution in patients with congestive heart failure, severe renal impairment, or conditions predisposing to fluid overload,Monitor serum electrolytes and acid-base balance regularly,Contains aluminum, which may be toxic with prolonged use in renal impairment,Risk of hyperkalemia in patients with renal failure or potassium-retaining medications
Risk of fluid overload, electrolyte disturbances, and hyperglycemia in patients with impaired renal function, cardiac failure, or diabetes,Use with caution in patients with severe hepatic disease (risk of lactic acidosis from acetate),Monitoring of serum electrolytes, glucose, fluid balance, and acid-base status is required,Avoid extravasation: risk of tissue necrosis
Hypersensitivity to any component,Severe hyperkalemia,Severe hypernatremia,Severe metabolic alkalosis,Patients with anuria or severe renal failure (relative)
Hyperkalemia, hypernatremia, hyperphosphatemia, hypocalcemia,Severe metabolic alkalosis or lactic acidosis,Anuria or severe oliguria,Addison's disease (risk of hyperkalemia),Known hypersensitivity to any component
No specific food interactions. Maintaining hydration and electrolyte balance with dietary intake may be considered, but no restrictions are required.
No specific food interactions. Patients should maintain a balanced diet as tolerated, but sodium and potassium intake may need monitoring or adjustment based on electrolyte status. Avoid excessive ingestion of high-sodium or high-potassium foods unless directed by clinician.
No known teratogenic effects in any trimester.
Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential ions and do not pose fetal risk when administered appropriately. Hyperglycemia from excessive dextrose may be associated with fetal macrosomia, neonatal hypoglycemia, and other metabolic disturbances, particularly in diabetic pregnancies. No specific trimester risks are identified for isotonic balanced solutions.
Excretion into human milk unknown; M/P ratio not applicable. Use with caution.
Dextrose and electrolytes are normal constituents of breast milk. Infusion of ISOLYTE H with 5% dextrose does not alter milk composition or supply significantly. No adverse effects on breastfed infants are anticipated. The M/P ratio is not applicable as these are endogenous substances; no accumulation expected.
No dosage adjustment required in pregnancy.
No specific dose adjustments for pregnancy; however, avoid excessive dextrose administration to prevent maternal hyperglycemia and fetal metabolic complications. Use with caution in gestational diabetes or preeclampsia; consider lower dextrose concentrations or rate adjustments based on maternal blood glucose and electrolyte levels.
PLASMA-LYTE A is a balanced electrolyte solution indicated for fluid resuscitation; monitor serum electrolytes, especially in renal impairment. It contains acetate and gluconate as bicarbonate precursors; use cautiously in patients with lactic acidosis. Do not administer simultaneously with blood products through same IV line due to risk of clotting. Verify container integrity and that no leaks are present before use.
ISOLYTE H with Dextrose 5% is a hypertonic solution (approx. 480 m Osm/L) used for fluid and electrolyte replacement in patients with hypochloremic metabolic alkalosis and fluid losses. It should be administered through a central line due to its high osmolarity. Monitor serum electrolytes, glucose, and acid-base status. Do not administer if solution is discolored or contains particulate matter.
This solution is given through a vein to restore body fluids and electrolytes.,Tell your healthcare provider if you have any allergies or medical conditions like kidney disease.,Inform your provider if you are pregnant or breastfeeding.,Report any signs of allergic reaction: rash, itching, swelling, severe dizziness, trouble breathing.,During infusion, notify your nurse if you experience pain, redness, or swelling at the IV site.,Do not stop the infusion or adjust the rate on your own.
This IV solution provides fluids, electrolytes, and calories to help correct imbalances caused by illness or surgery.,Tell your healthcare provider if you have a history of heart failure, kidney disease, or diabetes, as this solution may affect these conditions.,You may experience discomfort at the IV site; report any pain, redness, or swelling immediately.,Regular blood tests will be needed to monitor your electrolyte levels and kidney function.,Do not stop or adjust the infusion rate on your own.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE A IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE A IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Maintenance and restoration of fluid and electrolyte balance; provides isotonic crystalloid solution with sodium, potassium, magnesium, chloride, and acetate/bicarbonate precursors to buffer acidity.. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE A IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Intravenous Electrolyte Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE A IN PLASTIC CONTAINER is: Intravenous infusion; adult dose is based on electrolyte and fluid requirements, typically 500-1000 m L/hour initially, then adjusted; maximum rate 30 m L/kg/hour.. The standard adult dose of ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE A IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE A IN PLASTIC CONTAINER is classified as Category C. No known teratogenic effects in any trimester.. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.